Positive enhancement of Lactobacillus fermentum HY01 on intestinal movements of mice having constipation
Lactobacilli have been used to treat many gastrointestinal disorders. But the outcome of Lactobacilli are strain specific. The strain Lactobacillus Fermentum, HY01, (LF-HY01) has a good performance in the environment of gastrointestinal tract. In this study, the aim is to investigate the preventive effects of LF-HY01 against activated-carbon-induced constipation in mice. Mice are randomized into four groups. Normal group was fed a normal diet, model group also has the same with activated carbon treatment, and low and high concentration groups are treated with LF-HY01. We have determined many indexes such as body weight, water content in faeces, defecation conditions, the level of small intestinal villi damages and levels of various neurotransmitters in serum, including motilin (MTL), gastrin (GT), endothelin (ET), somatostatin (SST), acetylcholinesterase (AchE), substance P (SP), and vasoactive intestinal peptide (VIP). LF-HY01 has no significant difference in each group, but it can significantly improve water content of faeces, defecation time of first black stool and activated carbon propelling rate in small intestine as compared of model group. Furthermore, LF-HY01 can effectively prevent small intestinal villi damages, which is less than that of model group. Moreover, LF-HY01 has the consistency to increase the levels of MTL, GT, ET, AchE, SP and VIP, and LF-HY01 can also have the ability to reduce the level of SST. These results suggest that Lactobacillus Fermentum, HY01, has a great impact in enhancing intestinal peristalsis ability and has the ability to prevent from activated-carbon-induced constipation in mice.
KeywordsActivated carbon Constipation Intestinal movement Lactobacillus Fermentum Traditional fermented yak yoghurt
This work was partly supported by Special Fund for Agro-scientific Research in the Public Interest (201303085), the People’s Livelihood Science and technology innovation Foundation of Chongqing (cstc2015shmszx80021), Fundamental Research Funds for the Central Universities (XDJK2016A018), Research Project of Sichuan Key Laboratory of Bamboo Diseases and Insect Pests Prevention and Control, and Resource Development (17ZZ016), the Construction Program of Chongqing Collaborative Innovation Center for Functional Food, Chongqing University of Education (167001) and Chongqing Research Program of Basic Research and Frontier Technology (cstc2016jcyjA0339), China.
- 5.Lebedeva MA, Karganov MY, Kozlova YA, Gotovtceva GN, Tumurov DA, Gudkova AA, Guekht AB (2014) The role of autonomic dysfunction in pathogenesis of irritable bowel syndrome. Patol Fiziol Eksp Ter 3:37–44Google Scholar
- 9.Allescher HD, Kurjak M, Huber A, Trudrung P, Schusdziarra V (1996) Regulation of VIP release from rat enteric nerve terminals: evidence for a stimulatory effect of NO. Am J Physiol 271:G568–G574Google Scholar
- 13.Xia LP, Jiang Y (2016) Effect of probiotics in prevention and treatment of allergic diseases in children. Chin J Contemp Pediatr 18:189–194Google Scholar
- 17.Wang IK, Lai HC, Yu CJ, Liang CC, Chang CT, Kuo HL, Yang YF, Lin CC, Lin HH, Liu YL, Chang YC, Wu YY, Chen CH, Li CY, Chuang FR, Huang CC, Lin CH, Lin HC (2012) Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol 78:1107–1112CrossRefGoogle Scholar
- 19.Kannampalli P, Pochiraju S, Chichlowski M, Berg BM, Rudolph C, Bruckert M, Miranda A, Sengupta JN (2014) Probiotic Lactobacillus rhamnosus GG (LGG) and prebiotic prevent neonatal inflammation-induced visceral hypersensitivity in adult rats. Neurogastroenterol Motil 26:1694–1704CrossRefGoogle Scholar
- 20.MacLaren R, Kuhl DA, Gervasio JM, Brown RO, Dickerson RN, Livingston TN, Swift K, Headley S, Kudsk KA, Lima JJ (2000) Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. Crit Care Med 28:438–444CrossRefGoogle Scholar
- 29.Wan Y, Corman S, Gao X, Liu S, Patel H, Mody R (2015) Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. Am Health Drug Benefits 8:93–102Google Scholar
- 30.Ojetti V, Ianiro G, Tortora A, D’Angelo G, Di Rienzo TA, Bibbo S, Migneco A, Gasbarrini A (2014) The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointes Liver Dis 23:387–391Google Scholar
- 32.Presti I, D’Orazio G, Labra M, B La Ferla, Mezzasalma V, Bizzaro G, Giardina S, Michelotti A, Tursi F, Vassallo M, Di Gennaro P (2015) Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect. Appl Microbiol Biot 99:5613–5626CrossRefGoogle Scholar
- 37.Zhou XD, Liu AP, Zhang M, Guo HY, Ren FZ (2012) Laxative Effect of Lactobacillus paracasei subsp.paracasei LC-01 in Constipated Mice. J Dairy Sci Technol 35:7–11Google Scholar
- 38.McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 11:CD008716Google Scholar
- 41.Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, ONeill G, Van Der Ploeg LHT, Evans J, Patchett AA, Smith RG, Howard AD (1991) Receptor for motilin identified in the human gastrointestinal system. Science 284:2184–2188CrossRefGoogle Scholar